Through the rapid clinical development of groundbreaking therapies aimed at empowering patients and their families around the world with the freedom to live their best lives.
Using pioneering computational biology methods, we have identified multiple families of peptides that are potent regulators of vascular homeostasis. Our clinical candidates are derived from these peptides and work through naturally existing, highly evolved, and self-regulating mechanisms of homeostasis that maintain our health and well-being.
Location: United States, Maryland, Baltimore
Total raised: $50M
Investors 3
| Date | Name | Website |
| - | Johns Hopk... | ventures.j... |
| - | Rapha Capi... | raphacap.c... |
| 02.11.2022 | Xontogeny | xontogeny.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 26.07.2023 | Series A | $10M | - |
| 29.06.2020 | Series A | $35M | - |
| 15.11.2018 | - | $5M | - |
Mentions in press and media 18
| Date | Title | Description |
| 26.07.2023 | AsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107 | - |
| 26.07.2023 | AsclepiX Therapeutics Raises $10M in Series A-3 Funding | AsclepiX Therapeutics, a Baltimore, MD-based clinical-stage biotech company leveraging computational biology to develop peptides for improved treatments of retinal diseases, raised $10M in Series A-3 funding. The round was led by Perceptive... |
| 19.03.2021 | Power Moves: Stanley Black & Decker appointed a new chief diversity officer | Power Moves is a column where we chart the comings and goings of talent across the region. Got a new hire, new gig or promotion? Tell us: baltimore@technical.ly. Stanley Black & Decker has appointed Morgan State University alum Joe Simm... |
| 29.06.2020 | Biopharmaceutical Company AsclepiX Therapeutics Raises $35 Million | AsclepiX Therapeutics — a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular homeostasis for the treatment of retinal and other important diseases — announced that it raised $35 milli... |
| 26.06.2020 | AsclepiX Therapeutics eyeing clinical trials after closing $35M Series A | Remington-based biotech company AsclepiX Therapeutics raised $35 million in funding for clinical trials of the treatment it is developing for eye diseases that are leading causes of blindness in adults. The Series A round was led by the Per... |
| 24.06.2020 | AsclepiX Therapeutics Announces $35 Million Series A Financing | Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials Series A financing led by the Perceptive Xontogeny Venture Fund BALTIMORE–(BUSINESS WIRE)–June 24, 2020– AsclepiX Therapeutics, Inc.... |
| 24.06.2020 | AsclepiX Therapeutics Raises $35M Series A | BALTIMORE--(BUSINESS WIRE)--AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular homeostasis for the treatment of retinal and other important diseases, to... |
| 24.06.2020 | AsclepiX Therapeutics Announces $35M Series A | BALTIMORE, MD, AsclepiX Therapeutics has closed a $35 million Series A financing led by Perceptive Xontogeny Venture Fund. >> Click here for more funding data on AsclepiX Therapeutics >> To export AsclepiX Therapeutics fundi... |
| 24.06.2020 | AsclepiX Therapeutics Raises $35M in Series A Financing | AsclepiX Therapeutics, Inc., a Baltimore, MD-based biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular homeostasis for the treatment of retinal and other important diseases, closed a $... |
| 15.11.2018 | Daily funding roundup - November 15th, 2018 | DUST Identity raised $2.3M; RoadBotics raised $3.9M; Ezra raised $4M; Shyft raised $6.5M DUST Identity: DUST Identity is a proprietary technology which utilizes to create an unclonable identity layer on any object. DUST Identity has raised ... |
Show more